Dataset from A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects

This study is designed to compare the efficacy and safety of simplifying therapy from a
regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a
regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV in virologically
suppressed, HIV-1 infected, HLA-B*5701 negative subjects for 48 weeks.

本研究旨在针对人类免疫缺陷病毒1型（HIV-1）感染且处于病毒学抑制状态、HLA-B*5701阴性的受试者，对比将治疗方案从阿扎那韦（atazanavir, ATV）+利托那韦（ritonavir, RTV）+替诺福韦/恩曲他滨（tenofovir/emtricitabine, TDF/FTC）简化为不含利托那韦的阿扎那韦（ATV）+硫酸阿巴卡韦/拉米夫定（abacavir sulfate/lamivudine, ABC/3TC）方案的有效性与安全性，研究周期为48周。